This study investigates pancreatic cancer. The purpose of this study is to construct an immune map to understand how pancreatic cancer evolves over time.
The study evaluates the immune system's role in the development and treatment of pancreatic cancer. It focuses on identifying changes in immune parameters and developing models for early diagnosis.
- Who can participate: Adults with primary pancreatic ductal adenocarcinoma (PDAC) or benign pancreatic tumors can participate. Healthy individuals without liver, gallbladder, or pancreas diseases are also eligible.
- Study details: Participants will provide clinical samples to map the immune landscape of pancreatic cancer. Some may receive an inactive substance called a placebo, which looks like the investigational medicine but does not contain any medicine.
How understandable was the trial content above?
Hard to understand
Easy to understand